BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35875964)

  • 21. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.
    Maschan M; Caimi PF; Reese-Koc J; Sanchez GP; Sharma AA; Molostova O; Shelikhova L; Pershin D; Stepanov A; Muzalevskii Y; Suzart VG; Otegbeye F; Wald D; Xiong Y; Wu D; Knight A; Oparaocha I; Ferencz B; Roy A; Worden A; Kruger W; Kadan M; Schneider D; Orentas R; Sekaly RP; de Lima M; Dropulić B
    Nat Commun; 2021 Dec; 12(1):7200. PubMed ID: 34893603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
    Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitive detection of integrated and free transcripts in chimeric antigen receptor T-cell manufactured cell products using droplet digital polymerase chain reaction.
    Wiltshire TD; Milosevic D; Jacob EK; Grebe SK; Dietz AB
    Cytotherapy; 2021 May; 23(5):452-458. PubMed ID: 33715950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.
    García-Calderón CB; Sierro-Martínez B; García-Guerrero E; Sanoja-Flores L; Muñoz-García R; Ruiz-Maldonado V; Jimenez-Leon MR; Delgado-Serrano J; Molinos-Quintana Á; Guijarro-Albaladejo B; Carrasco-Brocal I; Lucena JM; García-Lozano JR; Blázquez-Goñi C; Reguera-Ortega JL; González-Escribano MF; Reinoso-Segura M; Briones J; Pérez-Simón JA; Caballero-Velázquez T
    Front Immunol; 2023; 14():1152498. PubMed ID: 37122702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients.
    Schubert ML; Berger C; Kunz A; Schmitt A; Badbaran A; Neuber B; Zeschke S; Wang L; Riecken K; Hückelhoven-Krauss A; Müller I; Müller-Tidow C; Dreger P; Kröger N; Ayuk FA; Schmitt M; Fehse B
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35294040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.
    Jena B; Maiti S; Huls H; Singh H; Lee DA; Champlin RE; Cooper LJ
    PLoS One; 2013; 8(3):e57838. PubMed ID: 23469246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
    Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
    J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
    Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
    Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo.
    Yin Y; Zhang P; He L; Guo X; Wang H; Li J; Xu Q
    Evid Based Complement Alternat Med; 2022; 2022():1227308. PubMed ID: 36034960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basic Procedures for Detection and Cytotoxicity of Chimeric Antigen Receptors.
    Mihara K; Yoshida T; Bhattacharyya J
    Methods Mol Biol; 2019; 1904():299-306. PubMed ID: 30539476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry.
    Zheng Z; Chinnasamy N; Morgan RA
    J Transl Med; 2012 Feb; 10():29. PubMed ID: 22330761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy.
    Guan Y; Zhang M; Zhang W; Wang J; Shen K; Zhang K; Yang L; Huang L; Wang N; Xiao M; Zhou J
    Front Oncol; 2021; 11():646499. PubMed ID: 33898316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Li C; Sun Y; Wang J; Tang L; Jiang H; Guo T; Liu L; Wu Y; Ai L; Xia L; Wu J; Lin Z; Qian Q; Hu Y; Mei H
    Front Immunol; 2021; 12():599493. PubMed ID: 34113336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR).
    Galli E; Viscovo M; Fosso F; Pansini I; Di Cesare G; Iacovelli C; Maiolo E; Sorà F; Hohaus S; Sica S; Bellesi S; Chiusolo P
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR.
    Schanda N; Sauer T; Kunz A; Hückelhoven-Krauss A; Neuber B; Wang L; Hinkelbein M; Sedloev D; He B; Schubert ML; Müller-Tidow C; Schmitt M; Schmitt A
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
    Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
    Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients.
    de la Iglesia-San Sebastián I; Carbonell D; Bastos-Oreiro M; Pérez-Corral A; Bailén R; Chicano M; Muñiz P; Monsalvo S; Escudero-Fernández A; Oarbeascoa G; Fernández-Caldas P; Gómez-Centurión I; Pion M; Gayoso J; Anguita J; Kwon M; Díez-Martín JL; Buño I; Martínez-Laperche C
    Transplant Cell Ther; 2024 Mar; 30(3):306.e1-306.e12. PubMed ID: 38184148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.